Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
Kidney Int
    August 2021
  1. LILL JK, Thiebes S, Pohl JM, Bottek J, et al
    Tissue-resident macrophages mediate neutrophil recruitment and kidney injury in shiga toxin-induced hemolytic uremic syndrome.
    Kidney Int. 2021;100:349-363.
    >> Share

  2. BOUWMEESTER RN, van de Kar NCAJ, Wetzels JFM
    Enough is enough: targeted eculizumab withdrawal in atypical hemolytic uremic syndrome.
    Kidney Int. 2021;100:265-268.
    >> Share

    July 2021
  3. SCIESIELSKI LK, Felten M, Michalick L, Kirschner KM, et al
    The circadian clock regulates rhythmic erythropoietin expression in the murine kidney.
    Kidney Int. 2021 Jul 29. pii: S0085-2538(21)00729.
    >> Share

  4. IKEDA Y
    Novel roles of HIF-PHIs in chronic kidney disease: the link between iron metabolism, kidney function, and FGF23.
    Kidney Int. 2021;100:14-16.
    >> Share

  5. ARICETA G, Dixon BP, Kim SH, Kapur G, et al
    The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment.
    Kidney Int. 2021;100:225-237.
    >> Share

    June 2021
  6. KOYUN M, Kaya Aksoy G, Comak E, Ozaltin F, et al
    Outcome of diacylglycerol kinase epsilon-mediated hemolytic uremic syndrome in an infant.
    Kidney Int. 2021;99:1500-1501.
    >> Share

    April 2021
  7. BABITT JL, Eisenga MF, Haase VH, Kshirsagar AV, et al
    Controversies in Optimal Anemia Management: Conclusions from a Kidney Disease Improving Global Outcomes (KDIGO) Conference.
    Kidney Int. 2021 Apr 8. pii: S0085-2538(21)00355.
    >> Share

    March 2021
  8. HANUDEL MR, Wong S, Jung G, Qiao B, et al
    Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
    Kidney Int. 2021 Mar 31. pii: S0085-2538(21)00354.
    >> Share

  9. FUCHS MAA, Broeker KAE, Schrankl J, Burzlaff N, et al
    Inhibition of transforming growth factor beta1 signaling in resident interstitial cells attenuates profibrotic gene expression and preserves erythropoietin production during experimental kidney fibrosis in mice.
    Kidney Int. 2021 Mar 8. pii: S0085-2538(21)00278.
    >> Share

    January 2021
  10. VILLE S, Le Bot S, Chapelet-Debout A, Blancho G, et al
    Atypical HUS relapse triggered by COVID-19.
    Kidney Int. 2021;99:267-268.
    >> Share

    November 2020
  11. NORIS M, Remuzzi G
    Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule?
    Kidney Int. 2020;98:1084-1087.
    >> Share

  12. HASSANEIN M, Liaqat A, Paratore DA, Vachharajani TJ, et al
    The Case | Arrhythmias in a patient with sickle cell disease on hemodialysis.
    Kidney Int. 2020;98:1357-1358.
    >> Share

    May 2020
  13. BROEKER KAE, Fuchs MAA, Schrankl J, Kurt B, et al
    Different subpopulations of kidney interstitial cells produce erythropoietin and factors supporting tissue oxygenation in response to hypoxia in vivo.
    Kidney Int. 2020 May 23. pii: S0085-2538(20)30542.
    >> Share

    April 2020
  14. WYATT CM, Drueke TB
    Inhibition of HIF prolyl-hydroxylase domain to correct anemia in patients with chronic kidney disease.
    Kidney Int. 2020;97:639-642.
    >> Share

    December 2019
    Ferric citrate: cardio- and renoprotective in chronic kidney disease?
    Kidney Int. 2019;96:1277-1279.
    >> Share

    November 2019
  16. EL KAROUI K, Boudhabhay I, Fremeaux-Bacchi V
    Atypical hemolytic uremic syndrome and hypertensive crisis.
    Kidney Int. 2019;96:1239.
    >> Share

    July 2019
  17. ELABD H, Rashid T, Elkholi M, Stokes MB, et al
    The Case | Acute kidney injury in an African woman with microangiopathic hemolytic anemia and HIV.
    Kidney Int. 2019;96:253-254.
    >> Share

    June 2019

  18. Wyatt CM, Drueke TB. High-dose IV iron for anemia correction in chronic kidney disease. Kidney Int. 2019;95:727-730.
    Kidney Int. 2019;95:1518.
    >> Share

    May 2019
  19. CAVERO T, Arjona E, Soto K, Caravaca-Fontan F, et al
    Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome.
    Kidney Int. 2019 May 31. pii: S0085-2538(19)30582.
    >> Share

  20. CHO ME, Hansen JL, Peters CB, Cheung AK, et al
    An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease.
    Kidney Int. 2019 May 15. pii: S0085-2538(19)30506.
    >> Share

  21. SELVASKANDAN H, Karavadra M, Paramesparan K, Glasby M, et al
    The Case | Microangiopathic hemolytic anemia in a young female.
    Kidney Int. 2019;95:1277-1278.
    >> Share

    April 2019
  22. WYATT CM, Drueke TB
    High-dose IV iron for anemia correction in chronic kidney disease.
    Kidney Int. 2019;95:727-730.
    >> Share

  23. DUINEVELD C, Wijnsma KL, Volokhina EB, van den Heuvel LPB, et al
    Placental passage of eculizumab and complement blockade in a newborn.
    Kidney Int. 2019;95:996.
    >> Share

    March 2019
    Iron and oxygen sensing: discovering intricate links.
    Kidney Int. 2019;95:482-484.
    >> Share

    February 2019
  25. ZECHER D, Banas B, Buttner-Herold M, Kirschfink M, et al
    The Case | A 78-year-old woman with acute kidney injury and hemolytic anemia.
    Kidney Int. 2019;95:473-474.
    >> Share

  26. IMERI F, Nolan KA, Bapst AM, Santambrogio S, et al
    Generation of renal Epo-producing cell lines by conditional gene tagging reveals rapid HIF-2 driven Epo kinetics, cell autonomous feedback regulation, and a telocyte phenotype.
    Kidney Int. 2019;95:375-387.
    >> Share

    January 2019
  27. LEE CJ, Smith DW, Gardiner BS, Evans RG, et al
    Stimulation of erythropoietin release by hypoxia and hypoxemia: similar but different.
    Kidney Int. 2019;95:23-25.
    >> Share

    November 2018
  28. MONTERO D, Lundby C
    Arterial oxygen content regulates plasma erythropoietin independent of arterial oxygen tension: a blinded crossover study.
    Kidney Int. 2018 Nov 29. pii: S0085-2538(18)30718.
    >> Share

  29. GANZ T
    Erythropoietin and iron-a conflicted alliance?
    Kidney Int. 2018;94:851-853.
    >> Share

    September 2018
  30. SUZUKI N, Matsuo-Tezuka Y, Sasaki Y, Sato K, et al
    Iron attenuates erythropoietin production by decreasing hypoxia-inducible transcription factor 2alpha concentrations in renal interstitial fibroblasts.
    Kidney Int. 2018 Sep 20. pii: S0085-2538(18)30515.
    >> Share

    June 2018
  31. ANUSORNVONGCHAI T, Nangaku M, Jao TM, Wu CH, et al
    Palmitate deranges erythropoietin production via transcription factor ATF4 activation of unfolded protein response.
    Kidney Int. 2018 Jun 7. pii: S0085-2538(18)30250.
    >> Share

    February 2018
  32. MERINERO HM, Garcia SP, Garcia-Fernandez J, Arjona E, et al
    Complete functional characterization of disease-associated genetic variants in the complement factor H gene.
    Kidney Int. 2018;93:470-481.
    >> Share

  33. HUERTA A, Arjona E, Portoles J, Lopez-Sanchez P, et al
    A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome.
    Kidney Int. 2018;93:450-459.
    >> Share

    January 2018
  34. TORO L, Barrientos V, Leon P, Rojas M, et al
    Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury.
    Kidney Int. 2018 Jan 27. pii: S0085-2538(17)30854.
    >> Share

    July 2017
  35. BROCKLEBANK V, Johnson S, Sheerin TP, Marks SD, et al
    Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.
    Kidney Int. 2017 Jul 24. pii: S0085-2538(17)30323.
    >> Share

    June 2017
  36. SUGAHARA M, Tanaka T, Nangaku M
    Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
    Kidney Int. 2017 Jun 24. pii: S0085-2538(17)30305.
    >> Share

  37. VAN LAECKE S, Van Biesen W
    Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect?
    Kidney Int. 2017;91:1271-1274.
    >> Share

    March 2017
  38. GOODSHIP TH, Cook HT, Fakhouri F, Fervenza FC, et al
    Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
    Kidney Int. 2017;91:539-551.
    >> Share

    November 2016
  39. RHEAULT MN, Molony JT, Nevins T, Herzog CA, et al
    Hemoglobin of 12 g/dl and above is not associated with increased cardiovascular morbidity in children on hemodialysis.
    Kidney Int. 2016 Nov 16. pii: S0085-2538(16)30539.
    >> Share

  40. WYATT CM, Drueke TB
    HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
    Kidney Int. 2016;90:923-925.
    >> Share

    September 2016
  41. PERGOLA PE, Spinowitz BS, Hartman CS, Maroni BJ, et al
    Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
    Kidney Int. 2016 Sep 17. pii: S0085-2538(16)30357.
    >> Share

    July 2016
  42. VANKALAKUNTI M, Vasavi B, Anitha A
    Intravascular large B-cell lymphoma: masquerade as membranoproliferative glomerulonephritis.
    Kidney Int. 2016;90:231-2.
    >> Share

    May 2016
  43. MARCELLI D, Bayh I, Merello JI, Ponce P, et al
    Dynamics of the erythropoiesis stimulating agent resistance index in incident hemodiafiltration and high-flux hemodialysis patients.
    Kidney Int. 2016 May 10. pii: S0085-2538(16)30056.
    >> Share

    March 2016
  44. GREENBAUM LA, Fila M, Ardissino G, Al-Akash SI, et al
    Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Kidney Int. 2016;89:701-11.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016